# Phase 2 Study of S-1 as 2nd Line Therapy in Metastatic Pancreatic Cancer

> **NCT00652054** · PHASE2 · COMPLETED · sponsor: **Taiho Oncology, Inc.** · enrollment: 39 (actual)

## Conditions studied

- Metastatic Pancreatic Cancer

## Interventions

- **DRUG:** S-1

## Key facts

- **NCT ID:** NCT00652054
- **Lead sponsor:** Taiho Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2007-06
- **Final completion:** 2007-10
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2024-09-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00652054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00652054, "Phase 2 Study of S-1 as 2nd Line Therapy in Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00652054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*